U.S. Software Stock News

If you are wondering whether Golar LNG is genuinely good value at its current share price, this article will walk through what the numbers are really saying about the stock. The share price sits at US$40.58, with returns of 6.4% over the last 30 days, 6.9% year to date, and a 3 year return of 90.6% alongside a 5 year return that is very large. Over the last 7 days and 1 year, the share price has shown modest declines of 0.8% and 3.2% respectively. Recent news around Golar LNG has focused on...

Liberty Global (LBTY.A) has drawn fresh attention as investors review its recent share performance, with the stock up around 4% over the past month and about 6% in the past 3 months. See our latest analysis for Liberty Global. Beyond the recent uptick, Liberty Global’s 7 day share price return of 5.69% and 90 day share price return of 6.29% contrast with a relatively flat 0.27% total shareholder return over the past year. This suggests short term momentum has picked up even as longer term...

If you are wondering whether DraftKings' share price reflects its true worth, you are not alone, the stock has attracted a lot of attention from investors trying to work out what a fair value looks like. Recently, the stock has been under pressure, with a 9.0% decline over the last 7 days, a 22.1% decline over 30 days, and a 23.6% decline year to date, even though the 3 year return stands at 64.8%. Over the past year, DraftKings has also seen a 35.8% decline, and over 5 years the return is a...

Recent share performance and business snapshot KKR (KKR) has been on many investors’ screens after a recent stretch of weaker returns, including about a 22% decline over the past month and roughly 12% over the past 3 months. The stock closed at US$104.77, while the firm reports revenue of US$22.25b and net income of US$2.27b. Its business model is built around private equity, real estate, and a wide range of credit and infrastructure investments globally. See our latest analysis for KKR. That...

If you are wondering whether Cintas is fairly priced or if the share price has already run ahead of its value, this article will walk you through what the current market is implying and how that compares with several valuation checks. Cintas shares recently closed at US$192.61, with returns of 1.8% over the last 7 days, 3.9% over 30 days, 4.2% year to date and a 3.7% decline over the past year, alongside longer term returns of 79.9% over 3 years and 131.1% over 5 years. Recent coverage has...

BancFirst Corporation reported past fourth-quarter 2025 results with net income of US$59.5 million and higher year-over-year earnings per share, alongside net charge-offs of US$1.6 million compared with US$985,000 a year earlier. This mix of improved profitability and rising loan charge-offs highlights how BancFirst is balancing earnings strength with evolving credit costs in its loan portfolio. We’ll now examine how BancFirst’s higher net income, despite increased charge-offs, shapes its...

If you are wondering whether OneMain Holdings is priced attractively right now, it helps to line up the recent share performance with what the underlying valuation signals are saying. The stock closed at US$63.20, with returns of 20.1% over 1 year, 77.7% over 3 years and 97.9% over 5 years. This is despite the share price having seen a 2.8% decline over 7 days, a 9.9% decline over 30 days and an 8.5% decline year to date. Recent coverage has focused on how consumer credit conditions, funding...

Ionis Pharmaceuticals (NasdaqGS:IONS) received European Commission approval for Dawnzera to help prevent hereditary angioedema attacks in eligible patients. The US FDA granted Breakthrough Therapy designation to zilganersen for Alexander disease, recognizing its potential for a serious rare condition with high unmet need. Partner GSK reported positive Phase 3 results for bepirovirsen, supporting potential regulatory filings for the hepatitis B candidate. Ionis Pharmaceuticals focuses on RNA...

Flowco Holdings (NYSE:FLOC) has entered a definitive agreement to acquire the parent company of Valiant Artificial Lift Solutions. The deal expands Flowco's artificial lift portfolio and broadens its presence in production optimization technologies. Management expects the transaction to be accretive to earnings and cash flow once completed. Flowco Holdings, trading at $22.15, is coming into this deal after mixed recent share performance, with the stock up 11.8% over the past week and 16.0%...

If you are wondering whether Ventas is still reasonably priced after its recent run, this article walks through what the current share price might be implying about its value. Ventas shares last closed at US$77.73, with returns of 2.4% over the past week, 1.7% over the last month, 0.5% year to date, 31.3% over one year, 65.7% over three years and 85.8% over five years. This naturally raises questions about how much optimism is already reflected in the price. Recent coverage around Ventas has...

In January 2026, Vertiv launched Vertiv Next Predict, an AI-powered managed service that uses predictive analytics and anomaly detection to transform data center maintenance across power, cooling, and IT systems. This move deepens Vertiv’s role at the heart of AI data center infrastructure by tying its service expertise to a scalable, grid-to-chip AI operations platform designed to evolve with future technologies. We’ll now examine how this AI-driven maintenance offering could shape...

In recent sessions, ADMA Biologics reported growing analyst optimism ahead of its upcoming earnings release, supported by positive revisions to earnings estimates and recognition of its specialty focus in plasma-derived biologics for immune deficiencies and infectious diseases. An interesting angle is ADMA’s integrated plasma collection and production model, which analysts view as central to its differentiation in the biologics market. Next, we’ll explore how this rising analyst confidence...

FIGS has recently launched a Winter Olympics campaign featuring Lindsey Vonn, extending its partnership with the USOPC and outfitting Team USA’s medical team, while selling a limited-edition FIGS x Team USA collection online and in stores. By spotlighting the healthcare professionals behind an elite athlete’s comeback, FIGS is tightly aligning its brand with high-performance medicine and national pride. We’ll now examine how this high-profile Lindsey Vonn and Team USA medical team campaign...

As the United States stock market begins February on a high note, with major indices like the Dow Jones and S&P 500 showing significant gains, investors are closely monitoring opportunities amidst fluctuating economic indicators. In this environment of heightened market activity and shifting economic policies, identifying undervalued stocks can be crucial for those looking to capitalize on potential discounts in the market.

As February 2026 begins, the U.S. stock market has shown strength with major indices like the Dow Jones and S&P 500 posting significant gains, buoyed by positive economic indicators such as an unexpected expansion in manufacturing activity. In this environment of heightened market optimism, identifying high-growth tech stocks involves focusing on companies that demonstrate robust innovation and adaptability to capitalize on emerging trends and technological advancements.

As February 2026 begins, U.S. stock indexes have shown a strong start with the Dow climbing 515 points and the S&P 500 nearing record highs, reflecting a positive sentiment in the market despite ongoing economic uncertainties such as delayed jobs reports and geopolitical tensions. In this environment of fluctuating indices and evolving trade dynamics, growth companies with high insider ownership can present intriguing opportunities for investors seeking robust revenue expansion, as these...

As February begins, the U.S. stock market has shown a robust start with major indexes like the Dow Jones Industrial Average and S&P 500 ending sharply higher. For those looking to invest in smaller or newer companies, penny stocks—despite their name's vintage feel—can still offer surprising value. This article explores three penny stocks that demonstrate financial strength and potential for long-term growth, offering an intriguing opportunity for investors seeking to diversify their...

As February 2026 unfolds, the U.S. stock market is experiencing a robust start with major indices like the Dow Jones and S&P 500 posting significant gains, reflecting optimism despite recent economic uncertainties such as delayed jobs data due to a government shutdown. In this dynamic environment, identifying promising small-cap stocks requires a keen eye for companies that not only demonstrate resilience in fluctuating economic conditions but also possess unique growth potential that can...

As February 2026 begins, major U.S. stock indexes have surged, with the Dow Jones Industrial Average gaining 515 points and the S&P 500 nearing a record high, reflecting investor optimism amid recent economic developments. In this buoyant market environment, dividend stocks can offer a compelling opportunity for investors seeking steady income and potential growth, especially as companies continue to navigate evolving trade dynamics and economic policies.

Investors may be wondering whether ANI Pharmaceuticals is fairly priced at its recent levels, or if the market is overlooking something in the current share price. The stock closed at US$81.27, with returns of 2.2% over 7 days, 3.3% over 30 days, 3.6% year to date, 35.9% over 1 year, 81.2% over 3 years and 155.5% over 5 years. These figures may have some investors reassessing both upside potential and risk. Recent attention around ANI Pharmaceuticals has focused on its position within the...

InMode (NasdaqGS:INMD) confirmed it received a non binding proposal from Steel Partners Holdings L.P. to acquire a majority stake. The board has formed an independent committee to evaluate this proposal and consider a range of potential alternatives. The review process is underway and could result in a change of control or other significant outcomes for existing shareholders. InMode focuses on medical devices for aesthetic and wellness procedures, an area that sits at the intersection of...

Jacobs Solutions (J) opened fiscal Q1 2026 with revenue of about US$3.3b and basic EPS of US$1.12, setting the tone for how the year is starting after a busy 2025. The company has seen quarterly revenue move from roughly US$2.9b in Q1 2025 to US$3.3b in the latest quarter, while basic EPS shifted from a small loss of about US$0.10 to a profit of US$1.12, a swing that puts the focus firmly on how sustainable those margins prove to be. See our full analysis for Jacobs Solutions. With the...

In late January 2026, Nurix Therapeutics reported full-year 2025 revenue of US$83.98 million, up from US$54.55 million, alongside a wider net loss of US$264.46 million and an Employee Stock Ownership Plan-related shelf registration for up to 5,090,373 common shares worth about US$98.80 million. The results came as Nurix advanced its lead BTK degrader bexobrutideg into pivotal DAYBREAK development with Orphan Drug and Fast Track status, backed by partnerships with Gilead, Sanofi, and Pfizer...

NXP Semiconductors has completed the sale of its MEMS sensor business. The company is exiting new RF Power developments and winding down that activity. Management is concentrating resources on software-defined vehicles, physical AI, and industrial/IoT opportunities. These moves come as NXP adjusts its portfolio in the context of margin and inventory pressures. NXP Semiconductors (NasdaqGS:NXPI) is reshaping its business around areas it views as core to its future identity, while stepping...